RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024 “[Buyers] were sitting on the sidelines because of lot of uncertainties around macroeconomics and regulatory issues, but also geopolitical situations. But what we have said in our Firepower report is, they cannot sit on the sideline too long, because the patent cliff isn’t waiting for anybody,” EY's Subin Baral said.
“Just a matter of time”
“I think it was just a matter of time this was going to happen, and it is just happening now, as the LoE [loss of exclusivity] pressures are more imminent for a lot of these biopharma companies, and them having to go access this external innovation to fill the gap,” Baral added.
With the loss of patent protection for the blockbuster drug Enbrel ... For Amgen the time is now !
Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list of 10 drugs eligible for the first round of Medicare pricing negotiations. Now, the company is fighting back against a move in Colorado that aims to cap the med’s price at the state level.
In a recently filed lawsuit in Colorado federal court, Amgen is challenging a vote from the state’s newly created Prescription Drug Affordability Review Board. The board plans to subject the drug to an “upper payment limit,” local newspaper the Colorado Sun reports.
Amgen's claims that Colorado's decision violates the US Constitution has already been struck down in 3 US Federal Courts in their rulings involving the contitutionality of the IRA.
https://www.fiercepharma.com/pharma/amgen-facing-potential-enbrel-price-cap-colorado-takes-states-new-drug-affordability-board